Nasaq Elenjaz for Development and Commercial Investment

What Nasaq Elenjaz for Development and Commercial Investment does

NASAQ Al Enjaz for Development and Commercial Investment is a Riyadh-headquartered, privately held Saudi healthcare solutions provider operating across pharmaceutical trading, medical device distribution, and specialized logistics. Founded approximately 2014 under the leadership of Chairman Badr Al-Qurashi, the company serves all 13 administrative regions of Saudi Arabia through government tenders and direct B2B sales to healthcare institutions, with secondary consumer access via a public online product catalog. Its portfolio spans 1000+ premium products across five branded pharmaceutical sub-portfolios (CardioProtect, RespiraClear, DermaCare, DiabeControl, OncoCare) plus medical devices sourced from international manufacturers, with end-to-end services including installation, training, maintenance, and after-sales support.

The company operates SFDA-licensed warehousing with temperature-controlled cold chain logistics, GPS-enabled real-time tracking, and cloud-based inventory management systems. Supporting digital infrastructure includes AI-powered analytics for demand forecasting and supply chain optimization, and digital ordering platforms for healthcare providers. Regulatory foundation is built on SFDA licensing, ISO 13485:2016 Medical Devices Quality Management certification, and Good Distribution Practices (GDP) compliance. Distribution partnerships cover leading international pharmaceutical manufacturers and world-leading medical device manufacturers, enabling portfolio breadth across prescription drugs, OTC medicines, specialty pharmaceuticals, diagnostic equipment, and surgical instruments.

Revenue is generated through three streams: pharmaceutical trading and distribution (transaction-based unit pricing on 1000+ products), medical device distribution (hardware sales plus service packages), and specialized logistics services (temperature-controlled warehousing and cold chain management). The go-to-market is enterprise field sales targeting government healthcare institutions via tender processes, supplemented by direct B2B sales to private healthcare providers and a B2C online catalog. The company explicitly positions itself as national healthcare infrastructure supporting Saudi Arabia's Vision 2030 healthcare transformation, rather than as a foreign vendor-adapter. No external funding rounds, revenue figures, or headcount data are disclosed.

Name

Nasaq Elenjaz for Development and Commercial Investment

Legal name

NASAQ Al Enjaz for Development & Commercial Investment

Website

https://nasaq-sa.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

NASAQ Al Enjaz is a Riyadh-based, SFDA-licensed healthcare distributor serving all 13 regions of Saudi Arabia through pharmaceutical trading, medical device distribution, and cold chain logistics to government and private healthcare institutions under Vision 2030.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Healthcare Providers & Hospitals (TLAIALAE), Medical Devices & Diagnostics Temperature-Controlled Storage (TLALABAH), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Pharmaceutical distribution
• Medical device distribution
• Cold chain logistics
• Healthcare procurement services
• Pharmaceutical trading

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Infrastructure, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Trading and Distribution: Trading and distribution of prescription drugs, over-the-counter medicines, and specialty pharmaceuticals to healthcare providers across Saudi Arabia. Revenue generated through product sales to government and private healthcare institutions, fulfilling governmental tenders and ongoing supply contracts.
2. Medical Device Distribution: Distribution of medical equipment including diagnostic equipment, surgical instruments, and medical devices. Provides complete solutions including installation, training, maintenance, and after-sales support. Revenue from device sales and associated service packages.
3. Specialized Logistics Services: Temperature-controlled warehousing, cold chain management, and pharmaceutical inventory solutions for healthcare institutions. Provides specialized logistics as an additional revenue stream supporting the core distribution business.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

NASAQ Al Enjaz trades and distributes pharmaceutical products (branded SKUs across cardiovascular, respiratory, dermatology, diabetes, and oncology categories) and medical devices from international manufacturers to healthcare providers across all 13 regions of Saudi Arabia. It also operates SFDA-licensed temperature-controlled warehousing and cold chain logistics services for healthcare institutions, supported by digital ordering, cloud-based inventory management, and AI-driven analytics.

Product overview

NASAQ Al Enjaz operates as a healthcare solutions provider offering pharmaceutical trading, medical device distribution, and digital health solutions. The product portfolio includes branded pharmaceutical products across five therapeutic categories: CardioProtect (cardiovascular), RespiraClear (respiratory), DermaCare (dermatological), DiabeControl (diabetes), and OncoCare (oncology). Individual products include CardioProtect ACE 10mg (Enalapril Maleate), RespiraClear Broncho Inhaler (Salbutamol Sulfate), DiabeControl Extended Release 1000mg (Metformin Hydrochloride), OncoCare Supportive Care Tablets, and DermaCare Anti-Acne Gel. The company also provides cold chain logistics services, temperature-controlled warehousing, and medical device distribution as part of its integrated healthcare ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• CardioProtect: Cardiovascular care solutions for cardiovascular protection
• RespiraClear
• DermaCare
• DiabeControl
• OncoCare

Products and services

• Pharmaceutical Trading Services

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Leading International Pharmaceutical ManufacturerscoreChannel Partner/ Reseller/ DistributorNASAQ Al Enjaz partners with leading international pharmaceutical manufacturers to source high-quality prescription drugs, over-the-counter medicines, and specialty pharmaceuticals. These partnerships enable the company to maintain a comprehensive pharmaceutical portfolio while ensuring product quality meets SFDA and international standards. The company works with manufacturers to ensure reliable supply chains to Saudi Arabian healthcare providers.
• World-Leading Medical Device ManufacturerscoreChannel Partner/ Reseller/ DistributorPartnership with world-class medical device manufacturers to deliver innovative diagnostic equipment, surgical instruments, and advanced medical technology to Saudi Arabian healthcare institutions. Partners provide cutting-edge medical devices while NASAQ handles distribution, installation, training, maintenance, and after-sales support within the Kingdom.

Scale indicators5 records

Recent moves6 records

Expansion highlights10 records

Broad incumbents

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and GCC-wide distributor. Comparable in regional pharma distribution scale and government-tender positioning, but with broader geographic reach and a manufacturing-led model.
• Avalon Pharma: Saudi pharmaceutical company focused on branded generics and consumer health products, serving hospitals and retail. Comparable in Saudi market presence and branded pharma portfolio, though more retail-leaning than NASA's pure B2B/government focus.
• Tabuk Pharmaceuticals: Leading Saudi pharmaceutical manufacturer with strong government-tender presence across MENA. Comparable in targeting Saudi public healthcare procurement and owning a branded pharma portfolio, but is upstream manufacturing rather than distribution-focused.
• Neopharma: UAE-based pharmaceutical manufacturer with GCC distribution. Comparable in regional pharma distribution and government-tender participation, but with manufacturing-led value chain and broader Gulf footprint.
• Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Listed Saudi pharmaceutical manufacturer and distributor with broad generic and branded portfolios across MENA. Comparable in product breadth, government-tender access, and Saudi regulatory positioning, but operates as a manufacturer-distributor incumbent rather than a pure distributor.

Others

• Agility (Life Sciences Logistics): Kuwait-headquartered global logistics provider with a dedicated Life Sciences / cold-chain vertical. Comparable in pharmaceutical cold-chain capability and regional logistics infrastructure, but operates as a 3PL provider rather than a pharma distributor.
• DHL Life Sciences (DHL Supply Chain): Global contract logistics provider with dedicated life sciences cold-chain warehousing and GDP-compliant distribution in the Middle East. Comparable in pharmaceutical cold-chain capability and Saudi warehousing footprint, but as an enabling 3PL rather than a competing distributor.
• Aramex Healthcare: Regional logistics provider with healthcare and cold-chain capabilities across MENA. Comparable in temperature-controlled medical logistics and Saudi distribution, but as a courier/logistics specialist rather than a pharma/device wholesaler.

Direct peers

• Tamer Group: Saudi Arabia's largest pharmaceutical and consumer healthcare distributor, with nationwide reach and parallel medical device distribution. Directly comparable in product mix (pharma + devices + logistics), customer base (government and private hospitals), and Vision 2030-aligned positioning.
• Al-Jeel Medical & Trading: Long-established Saudi medical device and pharmaceutical distributor serving government hospitals and private providers. Closely comparable in dual pharma/device distribution model and Saudi tender-led GTM motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nasaq-elenjaz

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nasaq Elenjaz for Development and Commercial Investment